Covaxin: India to start human trial of Covid-19 vaccine in July
The human trial for the vaccine of the Covid-19 will start in July in India. Bharat Biotech is the latest company to announce a vaccine candidate COVAXIN has received permission for advancing to human trials. The Hyderabad-based vaccine major’s vaccine candidate COVAXIN has received permission for advancing to human trials. According to the firm, it is “India’s first vaccine candidate for COVID-19, developed in collaboration with the India Council of Medical Research (ICMR) -National Institute of Virology(NIV)”. Human clinical trials are scheduled to begin across India in July.
As per the company, the SARS-CoV-2 strain was isolated in NIV, Pune, and transferred to Bharat Biotech. “The indigenous, inactivated vaccine was developed and manufactured in Bharat Biotech’s BSL-3 (Bio-Safety Level 3) High Containment facility located in Genome Valley, Hyderabad, India,” it added.
“The proactive support and guidance from CDSCO have enabled approvals to this project. Our R&D and Manufacturing teams worked tirelessly to deploy our proprietary technologies towards this platform,” said Chairman and Managing Director, Krishna Ella.